66%) og i vigtigste sekundære endepunkter (middel log10 HBV DNA reduktion: - 5, 00 vs. - 4, 17, og PCR negativitet:
Among HBeAg-negative patients, differences in therapeutic response (78% vs 66%) and key secondary endpoints (mean log10 HBV DNA reduction: -5.00 vs -4.17, and PCR negativity: